Introduction
This paper analyzes the financial ratios of two pharmaceutical giants, Pfizer and GSK. In particular, the paper discusses liquidity, profitability, activity, and debt ratios that we derived from the companies’ annual reports (GSK, 2023; Pfizer, 2023). The calculated ratios are provided in Appendix A for Pfizer and Appendix B for GSK. The purpose of this paper is to identify the strengths and weaknesses of the two companies in terms of their financial performance between 2020 and 2022.
Liquidity Ratios
Pfizer’s liquidity, gauged by the Current Ratio and Quick Ratio, has shown a mild decline over the last three years, with the Current Ratio declining from 1.35 in 2020 to 1.22 in 2022, and the Quick Ratio mirroring this trend, falling from 1.04 to 1.00. This modest downward trajectory may be attributed to the company’s strategic decisions or to market factors affecting its current assets or liabilities. Despite the decline, Pfizer maintains ratios above 1, which typically signal a company’s ability to cover its immediate obligations. The importance of maintaining a ratio above one cannot be overstated, as it reflects the company’s ability to liquidate assets if needed without disrupting its operations.
Contrastingly, GSK has consistently reported lower liquidity ratios than Pfizer, with a Current Ratio of 0.91 and a Quick Ratio of 0.68 in 2022. These figures raise concerns about GSK’s liquidity management, particularly its ability to meet short-term debt obligations with its most liquid assets. A Current Ratio below one suggests that the company may not be able to pay off its short-term liabilities if they all came due at once, a situation that could lead to solvency issues if not managed correctly. Furthermore, the Quick Ratio, which excludes inventory from the assets count due to its less liquid nature, emphasizes the potential difficulty GSK might face in quickly converting its assets to cash.
Activity Ratios
Regarding activity ratios, Pfizer’s performance has evidently improved, especially in its management of receivables and payables. Days Receivable Outstanding has been significantly reduced, halving from 97.95 days in 2020 to 52.86 days in 2022, suggesting a more effective credit policy or collection process. This improvement directly impacts cash flow, providing Pfizer with more liquidity to reinvest or pay down debt. Likewise, the Days Payables Outstanding has decreased dramatically from 322.41 days in 2020 to 113.71 days in 2022. Such a shift may indicate a strategic shift in payment terms with suppliers or more favorable conditions that could help better manage cash outflows.
GSK’s activity ratios depict a different scenario with elongated cycles across the board. The remarkably high Days Payables Outstanding of 486.30 days in 2022 may indicate a deliberate strategy to extend payment terms to preserve cash on hand. While this could be beneficial for short-term cash flow, it may also reflect a strained relationship with suppliers or a reliance on extended credit, which could be precarious if not managed with due diligence.
Profitability Ratios
Profitability ratios are crucial for assessing how effectively a company can convert its activities into profits. Pfizer has been on an upward trajectory, with its ROE rising from 0.14 in 2020 to 0.33 in 2022, indicating it is generating more profit per share from its shareholders’ equity. Concurrently, the Net Profit Margin has increased from 0.22 to 0.31, suggesting that Pfizer is converting a higher proportion of its revenues into profits, a positive sign for investors and the company’s financial stability.
GSK’s profitability ratios, particularly in 2022, have improved, with ROE at 1.41 and Net Profit Margin at 0.51. Such figures not only dwarf Pfizer’s but also illustrate GSK’s remarkable ability to generate profit from its equity and to retain a substantial part of its revenue as profit. However, it’s important to consider the underlying factors that could be influencing these numbers, such as non-operating income, one-off events, or changes in tax rates.
Debt Ratios
Debt ratios shed light on a company’s financial leverage and its ability to meet its long-term obligations. Pfizer’s Debt-to-Equity Ratio has seen a decrease, indicating a shift towards less reliance on debt
financing, a prudent approach, particularly in uncertain economic times. The decline in this ratio from 1.43 in 2020 to 1.06 in 2022 may reflect the company’s initiatives to bolster its equity base, perhaps through retained earnings or issuing more equity. Moreover, the Times Interest Earned ratio has surged from 6.17 in 2020 to an impressive 36.44 in 2022, signaling that Pfizer’s earnings are more than sufficient to cover interest payments, which could attract investors looking for a stable company with a lower risk of financial distress.
GSK’s debt ratios present a more complex picture. The high Debt-to-Equity Ratio of 4.72 in 2022 indicates a company that is significantly leveraged, relying more on debt than equity to finance its operations. While leverage can enhance returns on equity during good times, it can also amplify losses and increase bankruptcy risk during downturns. The Times Interest Earned ratio, although improved to 7.81 in 2022 from 5.78 in 2021, suggests that GSK’s earnings provide a narrower coverage for its interest obligations. This metric warrants attention as it could signal vulnerability to increasing interest rates or declining earnings.
Strengths and Weaknesses
The financial ratios illuminate several strengths and weaknesses of Pfizer and GSK. Pfizer’s strong liquidity management, evidenced by maintaining Current and Quick Ratios above 1, reflects a robust capacity to fulfill short-term liabilities. Its improving profitability suggests efficient operations and a potentially rewarding investment opportunity. However, the declining trend in liquidity ratios could signal a need for closer monitoring to prevent it from becoming a pressing issue.
GSK’s financials reveal a company that has made significant strides in profitability in 2022, a strength that may appeal to investors seeking high returns. Nonetheless, the company’s high debt levels and potential liquidity challenges underscore its concerns. The management of short-term obligations and working capital needs scrutiny, especially in an environment where liquidity can be critical to sustaining operations and seizing growth opportunities.
Conclusion
In conclusion, Pfizer appears to be navigating its financial path with a more balanced and conservative approach. At the same time, GSK seems to be in a more precarious, albeit potentially more rewarding position. Each company’s strategy reveals a different approach to managing its financial structure: Pfizer emphasizes stability, while GSK may seek growth or operational expansion, albeit with higher associated risks. Both companies, however, have demonstrated the ability to adapt over the past few years, which will be essential as they move forward in a dynamic healthcare industry.
References
GSK. (2023). Annual report 2022.
Pfizer. (2023). Annual Report 2022.
Appendix A: Pfizer’s Financial Ratios

Appendix B: GSK’s Financial Ratios
